Seiko Diane Yamada to Aged
This is a "connection" page, showing publications Seiko Diane Yamada has written about Aged.
Connection Strength
0.350
-
Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? Gynecol Oncol. 2019 07; 154(1):177-182.
Score: 0.052
-
Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9.
Score: 0.039
-
Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20.
Score: 0.033
-
Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors. JCO Clin Cancer Inform. 2022 08; 6:e2200035.
Score: 0.016
-
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16.
Score: 0.012
-
Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens. Gynecol Oncol. 2018 06; 149(3):570-574.
Score: 0.012
-
Statin Use Significantly Improves Overall Survival in High-Grade Endometrial Cancer. Int J Gynecol Cancer. 2016 11; 26(9):1642-1649.
Score: 0.011
-
Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015 Apr; 137(1):119-24.
Score: 0.010
-
Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014 Feb 01; 120(3):344-51.
Score: 0.009
-
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40.
Score: 0.008
-
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):22-7.
Score: 0.008
-
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Dec; 127(3):506-10.
Score: 0.008
-
The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer. 2013 Jan 15; 119(2):325-31.
Score: 0.008
-
Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7.
Score: 0.008
-
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2012 Feb; 13(2):154-62.
Score: 0.008
-
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Apr; 125(1):54-8.
Score: 0.008
-
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2011 Nov; 123(2):182-6.
Score: 0.008
-
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):264-8.
Score: 0.007
-
Assessing gynecologic and breast cancer survivors' sexual health care needs. Cancer. 2011 Jun 15; 117(12):2643-51.
Score: 0.007
-
The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23.
Score: 0.007
-
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96.
Score: 0.007
-
Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009 May 01; 15(9):3196-204.
Score: 0.007
-
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9.
Score: 0.006
-
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65.
Score: 0.005
-
Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5546-53.
Score: 0.005
-
Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1432-8.
Score: 0.005
-
Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Nov 15; 57(4):1004-9.
Score: 0.004
-
Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1272-6.
Score: 0.004
-
Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Dec 01; 54(5):1388-96.
Score: 0.004
-
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002 Apr 01; 52(5):1330-7.
Score: 0.004
-
Outcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment. Gynecol Oncol. 2001 Dec; 83(3):513-7.
Score: 0.004
-
An alpha-fetoprotein-producing hepatoid adenocarcinoma of the endometrium. Gynecol Oncol. 2001 Nov; 83(2):418-21.
Score: 0.004
-
Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001 Sep; 82(3):456-63.
Score: 0.004
-
Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1145-53.
Score: 0.004
-
Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001 Aug 01; 50(5):1154-60.
Score: 0.004